ClinicalTrials.gg
CompletedNCT01278407Updated Jun 29, 2023Results posted

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

A Phase 3 interventional study of Donepezil 5 mg and Donepezil 10 mg in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed at 56 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).

Read the detailed description

This 52-week study consisted of 16-week randomized placebo-controlled (RCT, including 12-week Confirmatory Phase) and 36-week open-label extension phases. Of 142 DLB patients enrolled in the RCT phase (three arms: placebo, 5 mg, and 10 mg), 110 entered the extension phase. The placebo group of the RCT phase initiated active treatment at week 16, and the active groups maintained allocated treatment and dosages until week 24. After week 24, all patients received 10 mg. Dose reduction to 5 mg for safety concerns was allowed.

02

Conditions studied

  • Dementia With Lewy Bodies (DLB)

Keywords

  • DLB
  • Dementia with Lewy bodies
  • Lewy Body Disease
  • Dementia
  • E2020
  • Donepezil
  • Aricept
03

In context

Lewy Body Disease

239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.

This study's enrollment of 142 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.

Browse Lewy Body Disease studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed as probable dementia with Lewy bodies (DLB) according to the consensus diagnostic criteria for DLB
  2. Patients having caregivers throughout the study who submited written consent to cooperate with this study, who routinely stayed with patients 3 days or more a week (at least 4 hours a day), provided patients' information necessary for this study, assisted treatment compliance, and escorted the patients on required visits to study institution
  3. Clinical Dementia Rating (CDR) score ≥ 0.5
  4. (MMSE) score of 10 to 26

Exclusion criteria

Exclusion Criteria

  1. Patients diagnosed with Parkinson's disease with dementia (PDD)
  2. Patients who received anti-dementia drug therapy at the same institution
  3. Patients who received anti-dementia drug therapy within 12 weeks before start of Screening
  4. Patients with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, or a history of brain surgery causing unrecovered deficiency
  5. Patients with severe extrapyramidal disorders (Hoehn and Hahr staging score ≥ IV)
  6. Patients whose systolic blood pressure was less than 90 mmHg or pulse rate was less than 50 bpm at screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Placebo comparator
    Placebo - Confirmatory Phase

    Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.

    Drug: Donepezil matched placebo

  • Experimental
    Donepezil 5 mg - Confirmatory Phase

    Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.

    Drug: Donepezil 5 mg

  • Experimental
    Donepezil 10 mg - Confirmatory Phase

    Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.

    Drug: Donepezil 10 mg

  • Experimental
    Placebo to Donepezil (5 +10 mg) - Extension Phase

    Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.

    Drug: Donepezil 10 mg

  • Experimental
    Donepezil (5 +10 mg) - Extension Phase

    Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.

    Drug: Donepezil 10 mg

Interventions

  • Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg

    Also known as: E2020

  • Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg

    Also known as: E2020

  • DrugDonepezil matched placebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mini-Mental State Examination (MMSE) Score

    The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. Data are presented as change from baseline in mean MMSE +/- standard deviation.

    Time frame: Week 12 for Confirmatory Phase

  2. Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score

    The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 dementia with Lewy bodies (DLB)-relevant domains of sleep, and cognitive fluctuation \[reported as cognitive fluctuation inventory\]) were assessed. The score of each item was calculated as frequency (scale: 1=occasionally to 4=very frequently) x Severity (scale: 1=Mild to 3=Severe). The NPI-2 was calculated as the sum of the scores for hallucinations and cognitive fluctuation, to yield a possible total score of 0 to 24. Lower score=less severity. A negative change score from baseline indicated improvement. Data are presented as change from baseline in mean NPI-2 +/- standard deviation.

    Time frame: Week 12 for Confirmatory Phase

07

Results

Posted Nov 30, 2015

Participant flow

Confirmatory Phase
Participant flow — Confirmatory Phase
MilestonePlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhasePlacebo to Donepezil (5 +10 mg) - Extension PhaseDonepezil (5 +10 mg) - Extension Phase
Started46474900
Completed37314300
Not completed916600
Withdrew: Adverse event510100
Withdrew: Participant's choice35300
Withdrew: Other11200
Extension Phase
Participant flow — Extension Phase
MilestonePlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhasePlacebo to Donepezil (5 +10 mg) - Extension PhaseDonepezil (5 +10 mg) - Extension Phase
Started0004696
Completed0003466
Not completed0001230
Withdrew: Adverse event000716
Withdrew: Participant's choice000411
Withdrew: Other00013

Outcome measures

PrimaryChange From Baseline in Mini-Mental State Examination (MMSE) Score

The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. Data are presented as change from baseline in mean MMSE +/- standard deviation.

Time frame:
Week 12 for Confirmatory Phase
Reported as:
Mean · Units on a scale
Change From Baseline in Mini-Mental State Examination (MMSE) Score
Units on a scalePlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory Phase
Change From Baseline in Mini-Mental State Examination (MMSE) Score0.6 ± 3.01.4 ± 3.42.2 ± 2.9
PrimaryChange From Baseline in Neuropsychiatric Inventory (NPI-2) Score

The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 dementia with Lewy bodies (DLB)-relevant domains of sleep, and cognitive fluctuation \[reported as cognitive fluctuation inventory\]) were assessed. The score of each item was calculated as frequency (scale: 1=occasionally to 4=very frequently) x Severity (scale: 1=Mild to 3=Severe). The NPI-2 was calculated as the sum of the scores for hallucinations and cognitive fluctuation, to yield a possible total score of 0 to 24. Lower score=less severity. A negative change score from baseline indicated improvement. Data are presented as change from baseline in mean NPI-2 +/- standard deviation.

Time frame:
Week 12 for Confirmatory Phase
Reported as:
Mean · Units on a scale
Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score
Units on a scalePlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory Phase
Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score-2.0 ± 4.2-1.7 ± 4.3-2.9 ± 4.7

Adverse events

Collected over For each patient from first dose of study drug administration up to 30 days from last dose of study drug or up to approximately Week 12 for Confirmatory Phase and Week 52 for Extension Phase. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Confirmatory Phase—5/46 (10.9%)23/46 (50%)
Donepezil 5 mg - Confirmatory Phase—4/47 (8.5%)18/47 (38.3%)
Donepezil 10 mg - Confirmatory Phase—1/49 (2%)17/49 (34.7%)
Placebo to Donepezil (5 +10 mg) - Extension Phase—9/37 (24.3%)31/37 (83.8%)
Donepezil (5 +10 mg) - Extension Phase—12/96 (12.5%)62/96 (64.6%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhasePlacebo to Donepezil (5 +10 mg) - Extension PhaseDonepezil (5 +10 mg) - Extension Phase
Spinal compression fractureInjury, poisoning and procedural complications1/460/470/492/370/96
Myocardial infarctionCardiac disorders1/460/470/491/370/96
CataractEye disorders0/460/470/491/370/96
Inguinal herniaGastrointestinal disorders1/460/470/491/370/96
Femoral neck fractureInjury, poisoning and procedural complications1/460/470/491/370/96
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/460/470/491/370/96
Loss of consciousnessNervous system disorders0/460/470/491/371/96
AsphyxiaRespiratory, thoracic and mediastinal disorders0/460/470/491/370/96
NauseaGastrointestinal disorders0/461/470/490/371/96
PneumoniaInfections and infestations0/461/470/490/372/96
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlacebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhasePlacebo to Donepezil (5 +10 mg) - Extension PhaseDonepezil (5 +10 mg) - Extension Phase
NasopharyngitisInfections and infestations7/464/472/4918/3717/96
ContusionInjury, poisoning and procedural complications4/460/471/496/377/96
ParkinsonismNervous system disorders2/462/474/495/3712/96
DiarrhoeaGastrointestinal disorders2/461/471/494/376/96
EczemaSkin and subcutaneous tissue disorders2/460/470/494/371/96
ConstipationGastrointestinal disorders0/460/470/493/375/96
NauseaGastrointestinal disorders1/462/471/493/374/96
Hepatic function abnormalHepatobiliary disorders2/460/470/493/370/96
DizzinessNervous system disorders0/460/470/493/371/96
Sleep disorderPsychiatric disorders2/461/470/493/371/96

Baseline characteristics

The data is based on Full Analysis Set, defined as all the randomized patients who received the study drug at least once and had valid efficacy assessment data at more than one point.

Age, Continuous
Age, Continuous(Years)Placebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhaseTotal
Mean77.2 ± 6.178.8 ± 5.177.7 ± 6.877.9 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhaseTotal
Female27252880
Male17202158
Mini-Mental State Examination (MMSE) Score
Mini-Mental State Examination (MMSE) Score(Unit on a scale)Placebo - Confirmatory PhaseDonepezil 5 mg - Confirmatory PhaseDonepezil 10 mg - Confirmatory PhaseTotal
Mean20.3 ± 4.220.6 ± 4.120.3 ± 4.820.4 ± 4.3
08

Study locations

56 sites
  • Anjo-shi, Aichi, Japan
  • Nagoya-shi, Aichi, Japan
  • Toyokawa-shi, Aichi, Japan
  • Chiba-shi, Chiba, Japan
  • Fukui-shi, Fukui, Japan
  • Yoshida-gun, Fukui, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Omuta-shi, Fukuoka, Japan
  • Gifu-shi, Gifu, Japan
  • Mizunami-shi, Gifu, Japan
  • Fujioka-shi, Gunma, Japan
  • Maebashi-shi, Gunma, Japan
  • Kure-shi, Hiroshima, Japan
  • Miyoshi-shi, Hiroshima, Japan
  • Otake-shi, Hiroshima, Japan
  • Obihiro-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Himeji-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Yabu-shi, Hyogo, Japan
  • Bando-shi, Ibaraki, Japan
  • Hitachi-shi, Ibaraki, Japan
  • Kahoku-shi, Ishikawa, Japan
  • Morioka-shi, Iwate, Japan
  • Fujisawa-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Koshi-shi, Kumamoto, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Uji-shi, Kyoto, Japan
  • Sendai-shi, Miyagi, Japan
  • Higashimorokata-gun, Miyazaki, Japan
  • Ina-shi, Nagano, Japan
  • Kitaazumi-gun, Nagano, Japan
  • Matsumoto-shi, Nagano, Japan
  • Nishisonogi-gun, Nagasaki, Japan
  • Nagaoka-shi, Niigata, Japan
  • Sanjo-shi, Niigata, Japan
  • Tsubame-shi, Niigata, Japan
  • Yufu-shi, Oita, Japan
  • Osaka-shi, Osaka, Japan
  • Sakai-shi, Osaka, Japan
  • Sennan-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Ageo-shi, Saitama, Japan
  • Kasukabe-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Fuji-shi, Shizuoka, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Koto-ku, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Suginami-ku, Tokyo, Japan
09

References and documents

Publications

  • Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimers Res Ther. 2015 Feb 3;7(1):5. doi: 10.1186/s13195-014-0081-2. eCollection 2015. PubMed 25713600 ↗
  • Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015 Feb 3;7(1):4. doi: 10.1186/s13195-014-0083-0. eCollection 2015. PubMed 25713599 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2011
First posted
Jan 17, 2011
Start
Feb 2011
Primary completionActual
Mar 2013
CompletionActual
Apr 2013
Results first posted
Nov 30, 2015
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01278407
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jan 17, 2011
Start date
Feb 2011
Primary completion
Mar 2013
Completion
Apr 2013
Results posted
Nov 30, 2015
Last update
Jun 29, 2023

Study contacts

Masaki Nakagawa
study director · Neuroscience Clinical Development Section. JAC PCU
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion